



Innovation for Cellular Therapies

About Vycellix™, Inc.

Visit us on the web at:
www.Vycellix.com

Headquartered on the campus of the Moffitt Cancer Center, Tampa, Florida, **Vycellix, Inc.**, is a closely-held immunotherapy-focused, discovery company with the mission to fundamentally impact the challenges that currently prevail in the area of cell & gene based-therapies. The Company is engaged in the development of proprietary approaches for cell-based immunotherapeutic products and to improve patient outcomes.

Vycellix's scientific discoveries coupled with a portfolio of small molecules & RNA modulators address current limitations for cell & gene therapies, including the need to accelerate speed of production, lower costs, ensure end-cell viability and persistence, and improve patient outcomes. The Company's innovative solutions offer the potential to significantly optimize processes for: cell reprogramming; enhancing cell potency; and improving cell expansion. Additionally, the Company is leveraging its assets to develop an early-stage pipeline of multifaceted, next-generation NK cell therapies targeting hematological malignancies and solid tumors, including its **ReOpt-NK™** (Retargeted Optimized NK cell) therapy.



Proprietary Small Molecule & RNA Modulators for the Enhancement of Cell & Gene Therapies

Potential Best-in-Class Platforms for:

- T CELLS
- NK CELLS
- STEM CELLS
- OTHER CELLS

EXPANSION
VY-M
Improved Cell Proliferation with Conserved Function Capacity

TRANSDUCTION
VY-OZ
Superior Gene Modification Efficiency; Increases CRISPR/Cas9 Gene Editing Rates

POTENCY
VY-X
Boosts Effector Cell Cytotoxicity for Enhanced Serial Killing Capacity

Multifaceted, Next-Generation Immuno-Oncology Therapies

	DISCOVERY	PRECLINICAL DEVELOPMENT	IND FILING	INITIAL INDICATION
VY-101: ReOpt-NK™ (Retargeted Optimized NK Cell) Therapy			2021	Lymphoid Cancers
VY-201: VY-X sRNA Therapy			2021	Sarcomas
VY-202: VY-X Amplified NK Cell Therapy			2021	Multiple Myeloma
VY-301: Endogenous Cell Therapy			TBD	TBD
VY-401: Universal Cell Therapy			TBD	TBD

Collaborating with Scientists at Karolinska Institutet





Vycellix's pipeline products were all discovered by scientists at the world renowned Karolinska Institutet (KI) in Stockholm, Sweden.

KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.



Small Molecule & RNA Modulator Technologies Available for License:

Ex Vivo Platforms for Autologous & Allogeneic Cell Therapies



Improves Cell Expansion, Gene Modification Efficiency and Serial Killing Capacity for T Cell & NK Cell Therapies

Collaborations: Vycellix has entered into collaborative agreements with leading academic and commercial entities with the shared mission to develop next-generation immunotherapies. The Vycellix team will present at and/or attend the following 2019 events:

- Innate Killer Summit, March 19-21
- World Vaccine Congress, April 15-17
- ASCO Annual Meeting, May 31-June 4
- Meeting of the Society of Natural Immunity, Sept 30-Oct 3
- BioFlorida Annual Meeting, Oct 20-22
- BIO Investor Forum, Oct 22-23
- SITC Annual Meeting, Oct 30-Nov 3
- ASH Annual Meeting, Dec 7-10

Corporate Highlights:

- ✔ Portfolio of novel small molecule & RNA modulators represents immediate out-licensing opportunities, while maintaining rights to integrate those assets into pipeline of multifaceted, next-generation immuno-oncology cell therapies.
- ✔ All corporate assets are clear of any encumbrances with strong, robust intellectual property protections.
- ✔ Seasoned & dynamic management team with strong expertise in T cell & NK cell immunology, including cell engineering, gene editing, cell modulation and monoclonal antibody development.
- ✔ Poised to report new breakthrough discoveries with supporting data in leading peer-review journals and/or key scientific conferences.

Founding Leadership:



Evren Alici, M.D., Ph.D.: CEO & Chairman of the Board

Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



Hans-Gustaf Ljunggren, M.D., Ph.D.: Chief Medical Officer

Former Dean of Research, Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



Douglas W. Calder: President

Strategic Advisor to the NSU Cell Therapy Institute; former Executive VP & Officer roles at the Vaccine & Gene Therapy Institute (VGTI), Accentia Biopharmaceuticals, Viragen and Biovest International



Samuel Duffey, Esq.: Exec VP, General Counsel

CEO & General Counsel of ViraCell, a cellular bioprocessing company; former roles include CEO, President & General Counsel of Biovest International, a public cancer vaccine company, and senior attorney at SEC



Michael J. Keller, J.D.: Exec VP, Intellectual Property

CEO, Keller Life Science Law; former roles include Chief Patent Counsel for IVAX, partner at leading IP law firms, and technology transfer roles at the National Cancer Institute (NCI)

For more information contact:

Douglas W. Calder: President
Phone: 772-418-6302
dcalder@Vycellix.com
www.Vycellix.com

